Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth

Core Insights - AbbVie has established a significant neuroscience franchise, initially supported by Botox Therapeutic and Vraylar, now expanded to include Ubrelvy, Qulipta, and Vyalev [1][4] Sales Performance - Neuroscience segment sales represented over 17% of AbbVie's total revenues in the first nine months of 2025, driven by strong sales growth in Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, all showing double-digit increases year-over-year [2][9] - Vyalev generated $299 million in sales during the same period, contributing to the overall growth despite declines in older therapies like Duodopa [2] Future Projections - AbbVie anticipates neuroscience sales to reach $10.7 billion by the end of 2025, indicating a 19% growth compared to 2024 [3][9] - The company is preparing to enhance its neuroscience portfolio with new therapies, including tavapadon, a potential oral treatment for Parkinson's disease, which could launch later this year [4] Pipeline Expansion - AbbVie is heavily investing in expanding its neuroscience pipeline, including the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, aimed at treating major depressive disorder [5] Competitive Landscape - Key competitors in the neuroscience space include Biogen and Johnson & Johnson, both diversifying their portfolios with novel therapies [6][7] Valuation and Market Performance - AbbVie shares have outperformed the industry over the past year, trading at a P/E ratio of 21.41, above the industry average of 19.26 and its five-year mean of 13.53 [8][11] - The Zacks Consensus Estimate for AbbVie's 2025 EPS remains steady at $10.64, with a slight increase for 2026 from $14.40 to $14.42 [13]